This is a preview of subscription content, log in via an institution to check access.
Notes
Generic imatinib is expected to be available in the US in 2016.
Treatment costs were estimated using Truven Health Analytics MarketScan claims data from 2011−2012. Costs for imatinib after generic entry were estimated as follows: 100% cost of branded drug for first 6 months after generic entry, followed by 70% cost of branded drug for the next 6 months, and 20% thereafter.
Reference
Padula WV, et al. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute : 4 Mar 2016. Available from: URL: http://dx.doi.org/10.1093/jnci/djw003
Rights and permissions
About this article
Cite this article
Generic imatinib lowers cost of CML-CP treatment in the US. PharmacoEcon Outcomes News 749, 18 (2016). https://doi.org/10.1007/s40274-016-2905-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2905-8